Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy

Critical Reviews in Oncogenesis

Volumn 18, Issue 3, 2013, Pages 177-195

  Weinreb, Neal J ^a,b   Lee, Robert E ^c  

^a University Research Foundation for Lysosomal Storage Diseases   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cancer; Cancer phobia; Cause of death; Comorbidity; Gaucher disease; Metastasis; Proportional mortality

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BILE DUCT CANCER; BRAIN CANCER; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; COLORECTAL CANCER; COMORBIDITY; ENZYME REPLACEMENT; FAMILIAL CANCER; FEMALE; GALLBLADDER CANCER; GAUCHER DISEASE; GENE MUTATION; GLIOBLASTOMA; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LARYNX CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MOUTH CANCER; MYELOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SCHOOL CHILD; SOFT TISSUE SARCOMA; SOLID TUMOR; SPLENECTOMY; TUMOR CELL; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASMS; SPLENECTOMY; UNITED STATES; YOUNG ADULT;

EID: 84875359975     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2013005921     Document Type: Article

References (78)

1. Grabowski G, Kolodny E, Weinreb N, Rosenbloom B, Prakash-Cheng A, Kaplan P, Charrow J, Pastores G, Mistry P. Gaucher disease: Phenotypic and genetic variation. In: The Online Metabolic and Molecular Basis of Inherited Metabolic Disease, CR Scriver, Al Beaudet, D Valle, WS Slye, eds. New York: McGraw-Hill Publishers, Chapter 146.1, 2010. Available to subscribers at: http://genetics.accessmedicine.com Accessed September 1, 2011.
2. Weinreb NJ. Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opin Pharmacother. 2008;9:1987-2000.
3. Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, Taylor JS, Cole JA, Zimran A, Weinreb NJ. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis. 2011;46: 95-102.
4. Biegstraaten M, Mengel E, Maródi L, Petakov M, Niederau C, Giraldo P, Hughes D, Mrsic M, Mehta A, Hollak CE, van Schaik IN. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain. 2010;133:2909-19.
5. Chérin P, Rose C, de Roux-Serratrice C, Tardy D, Dobbelaere D, Grosbois B, Hachulla E, Jaussaud R, Javier RM, Noël E, Clerson P, Hartmann A. The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis. 2010;33:331-8.
6. Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005;105:4569-72.
7. Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis. 2005;34:197-200.
8. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Häussinger D, Hollak CE. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006;36:53-8.
9. Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009;84:208-14.
10. Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types-correlation with genotype and phenotype. Am J Hematol. 2010;85:340-345.
11. Choy FYM, Campbell TN. Gaucher disease and cancer: concept and controversy. Int J Cell Biol. 2011;2011:150450.
12. Hughes DA. Enzyme, substrate, and myeloma in Gaucher disease. Am J Hematol. 2009;84:199-201.
13. Simon MA, Cofta-Woerpel L, Randhawa V, John P, Makoul G, Spring B. Using the word 'cancer' in communication about an abnormal Pap test: finding common ground with patient-provider communication. Patient Educ Couns. 2010;81:106-12.
14. http://www.phobias-help.com/Ten_Most_Common_Phobias.html. Accessed January 2, 2012.
15. Vanderpool RC, Huang B. Cancer risk perceptions, beliefs, and physician avoidance in Appalachia: results from the 2008 HINTS Survey. J Health Commun. 2010;15 Suppl 3:78-91.
16. Packman W, Crosbie TW, Riesner A, Fairley C, Packman S. Psychological complications of patients with Gaucher disease. J Inherit Metab Dis.2006;29:99-105.
17. Alifrangis G, Koizia L, Rozario A, Rodney S, Harrignton M, Sommerville C, Peplow T, Waxman J. The experiences of cancer patients. QJM. 2011;104:1075-1081.
18. Sigal JJ, Claude Ouimet M, Margolese R, Panarello L, Stibernik V, Bescec S. How patients with less-advanced and more-advanced cancer deal with three death-related fears: an exploratory study. J Psychosoc Oncol. 2008;26:53-68.
19. Chantler M, Podbilewicz-Schuller Y, Mortimer J. Change in need for psychosocial support for women with early stage breast cancer. J Psychosocial Oncol. 2005;23:65-77.
20. Shaha M, Bauer-Wu S. Early adulthood uprooted: transitoriness in young women with breast cancer. Cancer Nursing. 2009;32:246-255.
21. Gotay CC. The experience of cancer during early and advanced stages: the views of patients and their mates. Soc Sci Med. 1984;18:605-613.
22. Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res. 1982;95:177-217.
23. http://www.cdc.gov/nchs/products/vsus.htm. Accessed January 2, 2012.
24. Hennekens CR, Buring JE, Mayrent SL, editors. Epidemiology in Medicine. Philadelphia: Lippincott, Williams & Wilkins. 1987;85-86.
25. Ayto R, Hughes DA. Gaucher disease and myeloma. Reviews in Oncogenesis 2012; this volume.
26. Hoffman RM. Screening for prostate cancer. New Engl J Med. 2011:365:2013-2019.
27. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559-1564.
28. Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer. 1993;72:219-224.
29. Weinreb NJ, Lee RE. Changing patterns of mortality in Gaucher disease prior to and following the advent of enzyme replacement therapy. Blood. 2004;104:Part 2: 36b (Abstract #3799)
30. Weinreb NJ, Deegan P, Kacina KA, Mistry P, Pastores GM, Velentgas P, Vom Dahl S. Life expectancy in Gaucher disease type 1. Am J Hematol. 2008;83:896-900.
31. http://www.ons.gov.uk/ons/rel/vsob1/mortality-statistics--deaths-registered-in-england-and-wales--series-dr-/2009/index.html. Accessed January 2, 2012.
32. Winfield SL, Tayebi N, Martin BM, Ginns EI, Sidransky E. identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res. 1997;7:1020-6.
33. Nam SY, Seo HH, Park HS, An S, Kim JY, Yang KH, Kim CS, Jeong M, Jin YW. Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls cell survival after ionizing radiation. J Biol Chem. 2010;285:31157-63.
34. Gilles F, Goy A, Remache Y, Shue P, Zelenetz AD. MUC-1 dysregulation as the consequence of a t(1:14)(q21:q32) translocation in an extranodal lymphoma. Blood. 2000;95:2930-6.
35. Fonseca R, Van Wier SA, Chang WJ, Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20:2034-40.
36. Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin. 2010;31:1165-71.
37. Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JM, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, Mckinnon, WC, Petrucelli NM, Bennet M, Trapnier AM. Essential elements of genetic cancer risk assessment, counseling and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Counsel. 2011. DOI 101007/s10897-011-9462-x.
38. http://seer.cancer.gov/csr/1975_2003/results_single/sect_01_table.11_2pgs.pdf. Accessed Jan 12, 2012.
39. Fredericksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118:6515-20.
40. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Eng J Med. 2011;365:2241-2.
41. Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rhem Dis. 2005;64:699-703.
42. Bourguet CC, Logue EE. Antigenic stimulation and multiple myeloma. A prospective study. Cancer. 1993;72:2148-54.
43. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen county, Denmark. Aliment Pharmacol Ther. 2004;19:287-93.
44. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007;50:839-55.
45. Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores G, Mistry PK. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis. 2010; 33:291-300.
46. Lowenfels AB, Domeliof L, Lindstrom CG, Bergman F, Monk MA, Sternby NH. Cholelithiasis, cholecystectomy, and cancer: a case-control study in Sweden. Gastroenterology. 1982;83:672-6.
47. Shao T, Yang YX. Cholecystectomy and the risk of colorectal cancer. Am J Gastroenterol. 2005;100:1813-20.
48. Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type 1 Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis. 2008;40:428-32.
49. Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE, Hollak CE, Aerts JM, Serlie MJ. Type 1 Gaucher disease, a glycosphingolipid storage disorder is associated with insulin resistance. J Clin Endocrinol Metab. 2008;93:845-851.
50. Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CE, Aerts JM, Groener JE. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta. 2008;389:109-13.
51. Ucar SK, Coker M, Argin M, Akman S, Kara S, Simsek DG, Darcan S. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight. Mol Genet Metab. 2009;96:50-1.
52. Fuller M. Sphingolipids: the nexus between Gaucher disease and insulin resistance. Lipids Health Dis. 2010;9:113. Review.
53. Aerts JM, Boot RG, van Eijk M, Groener J, Bijl N, Lombardo E, Bietrix FM, Dekker N, Groen AK, Ottenhoff R, van Roomen C, Aten J, Serlie M, Langeveld M, Wennekes T, Overkleeft HS. Glycosphingolipids and insulin resistance. Adv Exp Med Biol. 2011;721:99-119.
54. Klement RJ, Kammerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond). 2011; 8:75.
55. Percik R, Stumvoll M. Obesity and cancer. Exp Clin Endocrinol Diabetes. 2009;117:563-6.
56. Cerhan JR, Bernstein L, Severson RK, Davis S, Colt JS, Blair A, Hartge P. Anthropometrics, physical activity, related medical conditions, and the risk of non-Hodgkin lymphoma. Cancer Causes Control. 2005;16:1203-14.
57. Faulds MH, Dahlman-Wright K. Metabolic diseases and cancer risk. Curr Opin Oncol. 2012;24:58-61.
58. Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ, Brancati FL. A prospective study of the associations between treated diabetes mellitus and cancer outcomes. Diabetes Care. 2012;35:113-8.
59. Tabares-Seisdedos R, Dumont N, Baudot A, Valderas JM, Climent J, Valencia A, Crespo-Facorro B, Vieta E, Gómez-Beneyto M, Martínez S, Rubenstein JL. No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncology. 2011:12:604-8.
60. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21:697-707.
61. Aubourg A, Benboubker L, Picon L, Goupille P, Maillot F. Successful autologous stem cell transplantation in Gaucher disease patient with multiple myeloma. Am J Hematol. 2011;86:529-30.
62. Carreiro J, Balwani M, Grosskreutz C, Isola L, Malone A, Scigliano E, Osman K. A case report of secondary autograft failure due to Gaucher disease. Am J Hematol. 2008;83:937.
63. Bohm P, Kunz W, Horny HP, Einsele H. Adult Gaucher disease in association with primary malignant bone tumors. Cancer. 2001;91:457-62.
64. Leone JP, Dudek AZ. Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer. Anticancer Res. 2008;28:3937-40.
65. Berger J, Lecourt S, Vanneaux V, Rapatel C, Boisgard S, Caillaud C, Boiret-Dupré N, Chomienne C, Marolleau JP, Larghero J, Berger MG. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br J Haematol. 2010;150:93-101.
66. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155-66.
67. Hammarstedt A, Isakson P, Gustafson B, Smith U. Wnt-signaling is maintained and adipogenesis inhibited by TNF-alpha but not MCP-1 and resistin. Biochem Biophys Res Commun. 2007; 357:700-6.
68. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood. 2009;113:3139-3146.
69. Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternativelyactivatedmacrophages. Am J Clin Pathol. 2004;122:359-69.
70. Pandey MJ, Grabowski GA. Immunological cells and functions in Gaucher disease. Reviews in Oncogenesis 2012. This volume.
71. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell. 2009;16:167-179.
72. Schmidt T, Carmeliet P. Angiogenesis: A target in solid tumors, Also in leukemia? Hematology Am Soc Hematol Educ Program. 2011;2011:1-8.
73. Nyangoga H, Mercier P, Libouban H, Baslé MF, Chappard D. Three-dimensional characterization of the vascular bed in bonemetastasis of the rat by microcomputed tomography (MicroCT). PLos 1. 2011;6(3):e17336.
74. Lo SM, Liu J, Chen F, Pastores GM, Knowles J, Boxer M, Aleck K, Mistry PK. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J Inherit Metab Dis. 2011;34:643-50.
75. Pavlova EV, Deegan PB, Tindall J, MvFarlane I, Mehta A, Hughes D, Wraith JE, Cox JM. Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol Dis. 2011;46:27-33.
76. Zaidi M, Sun L, Robinson LJ, Tourkova IL, Liu L, Wang Y, Zhu LL, Liu X, Pang Y, Yang G, Shi X, Levine A, Iqbal J, Yaroslavskiy BB, Isales C, Blair HC. ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proc Natl Acad Sc USA. 2010;107:8782-7.
77. Mistry PK, Liu J, Yang M, Noholi T, McGrath J, Jain D, Zhang K, Keutzer J, Chang WL, Mehal WZ, Zhoo T, Lin A, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, Robinson LJ, Iqbal J, Sun L, Zaidi M. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Nat Acad Sci. 2010;107:19474-8.
78. Hollak CE, Aerts JM, Aymé S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 2011; 6:16.